Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2013

Mar 26, 2013

151_ip_2013-03-26_f8785646-3642-44ac-8909-cb5c6db4210e.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Fo d p by p rward step by step with Action Plan 2016

Evotec AG, Full-Year Results 2012, Frankfurt/Main, 26 March 2013

Forward-looking s statements

Information set forth in this presen forward-looking statements, whi number of risks and uncertainties. looking statements contained herein judgement of Evotec as of the presentation. Such forward-looki are neither promises nor guaran subject to a variety of risks and many of which are beyond our cont tation containsich involve aThe forward. forwardn represent the date of thising statements ntees, but are d uncertainties trol, and which

could cause actual results to differ materially from those contemplated in these forward looking statements We expressly disclaim any statements.obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on uncertainties, which any such statement is based based.

Welcome from thee Evotec management team

FY 2012

Agenda

•Highlights 2012

  • • Financial performance 2 2012
  • • Update on Action Plan 2 2016
  • •Outlook

Strong foundation n for further growth

Highlights & lowlights 201 12

H
i
h
l
i
h
t
g
g
s		 ®
/
f
f
A
d
d
T
2
d
P
h
I
I
I
d
D
i
P
2
t
t
7
7
n
r
o
m
e
a
e
v
a
s
r
o
n
g
p
r
o
g
r
e
s
s
o
n
a
s
e
s
u
y
o
a
e
p
•
(
)
R
R
h
h
d
d
i
i
i
i
f
f
i
i
P
P
h
h
I
I
b
i
d
i
i
A
A
l
l
h
h
i
i
'
's
d
d
i
i
A
D
t
t
t
t
t
t
t
t
t
t
o
c
e
s
a
r
e
s
g
n
c
a
n
a
s
e
n
n
m
o
e
r
a
e
s
e
e
r
e
m
e
r
s
e
a
s
e
v
y
z
•
C
(
)
l
i
i
l
N
M
D
A
f
l
i
E
V
T
1
0
0
i
l
i
l
l
i
d
J
t
t
t
n
c
a
s
a
g
e
p
o
r
o
o
s
e
r
e
s
e
c
s
e
c
e
n
s
e
o
a
n
s
s
e
n
x
u
v
y
•
C
B
l
l
i
i
h
J
f
h
h
f
d
i
b
t
t
t
t
t
t
t
r
e
e
a
a
a
n
c
e
a
n
s
s
e
n
o
r
e
r
e
a
m
e
n
o
a
e
e
s
u
w
•
S
i
f
l
i
i
h
i
i
i
l
l
i
i
i
h
h
B
B
h
h
i
i
I
I
l
l
h
h
i
i
t
t
t
t
t
t
r
o
n
g
p
r
o
g
r
e
s
s
n
p
o
r
o
o
s
n
e
e
s
n
g
a
a
n
c
e
s
e
e
g
g
o
o
e
e
r
r
n
n
g
g
e
e
r
r
n
n
g
g
e
e
e
e
m
m
w
x
w
w
•
,
M
d
I
N
i
t
e
m
m
n
e
o
a
r
s
u
v
,
M
l
i-
l
l
b
i
i
h
B
i
d
i
i
d
i
d
i
t
t
t
t
t
t
t
a
r
g
e
c
o
a
o
r
a
o
n
a
e
r
n
e
n
o
m
e
r
o
s
s
a
n
a
s
s
o
c
a
e
p
a
n
u
w
y
•
H
i
h
l
i
i
l
l
i
i
h
b
i
h
d
d
i
Y
l
U
i
i
H
d
t
t
t
t
g
g
n
n
o
a
e
n
e
a
a
n
c
e
s
o
e
c
a
n
a
c
a
e
m
a
e
g
a
e
n
e
r
s
a
r
a
r
y
y
v
v
w
w
v
y
y
v
•
,
,
,
U
i
i
A
i
t
n
e
r
s
p
e
r
o
n
v
y
,
C
C
E
i
f
d
i
l
l
i
i
h
H
D
I
F
d
i
f
H
i
's
d
i
(
H
D
)
t
t
t
t
t
e
n
s
o
n
o
s
c
o
e
r
a
a
n
c
e
o
n
a
o
n
o
r
n
n
g
o
n
s
e
a
s
e
x
v
y
w
u
u
•
S
i
l
l
i
i
h
A
i
b
d
4
t
t
t
t
r
a
e
g
c
a
a
n
c
e
n
o
w
y
•
-
1
)
C
C
S
A
i
i
i
f
t
c
q
s
o
n
o
u
•
C
l
i
i
i
l
i
l
d
i
i
i
d
i
h
l
l
l
i
(
N
I
H
)
t
t
t
t
e
a
r
p
o
s
o
n
n
g
a
s
q
a
e
a
e
r
n
s
e
r
c
e
n
s
r
s
e
e
r
a
n
e
a
a
n
c
e
s
e
g
u
y
v
u
y
w
v
w
•
L
l
i
h
t
o
w
g
s		 D
D
l
l
i
i
i
i
l
l
h
h
i
i
t
t
t
t
e
a
y
n
m
e
s
o
n
e
a
c
e
v
e
m
e
n
•
f
P
i
b
i
l
i
b
l
2
0
1
1
t
t
r
o
a
y
e
o
w
•
V
R
1
i
i
t
p
r
o
g
r
a
m
m
e
m
p
a
r
m
e
n
•

A solid year 2012 w with a positive outlook for 2013

Financial summary 2012

G
t
h
i
r
o
w
n
r
e
v
e
n
u
e
,
f
h
l
d
c
a
s
o
w
a
n
l
i
i
d
i
t
q
u
y		 l
i
h
€
9
%
8
8
7
3
t
t
t
o
p
n
e
g
r
o
o
m
w
•
-
)
1
f
A
d
j
d
i
l
€
1
4
i
l
i
i
h
d
j
d
i
d
t
t
t
t
t
t
u
s
e
o
p
e
r
a
n
g
r
e
s
u
o
m
n
n
e
w
a
u
s
e
g
u
a
n
c
e
•
f
1
8
%
h
€
1
2
0
i
i
i
i
h
l
t
t
t
t
g
r
o
w
o
m
n
p
o
s
v
e
o
p
e
r
a
n
g
c
a
s
o
w
•
L
i
i
d
i
i
€
6
4
4
2
t
t
q
n
c
r
e
a
s
e
o
m
u
y
•
f
f
I
t
t
n
v
e
s
m
e
n
s
o
o
r
r
h
i
h
i
t
i
g
e
r
n
n
o
a
o
n
v
f
f
i
i
e
c
e
n
c
y		 S
f
C
f-
f
i
i
i
A
P
E
X
i
i
h
h
l
d
d
i
t
t
t
t
t
t
t
t
t
t
t
t
t
g
n
c
a
n
n
v
e
s
s
m
e
n
s
n
s
s
a
a
e
e
-o
e
-a
a
r
r
e
c
n
o
o
g
y
a
a
n
n
n
r
a
s
r
u
c
u
r
e
•
f
d
€
8
2
u
p
g
r
a
e
o
m
F
d
i
i
h
i
h
l
i
i
d
i
h
d
t
t
t
o
c
s
e
n
e
s
m
e
n
s
n
g
n
n
o
a
e
s
c
o
e
r
r
e
s
e
a
r
c
a
r
e
a
s
a
n
u
v
y
v
v
v
y
•
f
d
i
l
l
i
€
8
8
3
a
c
a
e
m
c
a
a
n
c
e
s
o
m
S
t
t
l
k
r
o
n
g
o
u
o
o
f
2
0
1
3
o
r		 S
d
b
k
d
i
l
i
i
i
d
i
t
t
t
t
t
r
o
n
g
o
r
e
r
o
o
a
n
m
m
e
s
o
n
e
o
p
p
o
r
u
n
e
s
n
c
a
e
•
f
€
9
9
0
0
1
1
0
0
0
0
i
2
0
1
3
r
e
v
e
n
u
e
s
o
m
n
-
f
f
I
i
l
l-
i
b
i
l
i
d
h
d
d
i
l
t
t
t
t
t
t
t
n
c
r
e
a
s
n
g
u
y
e
a
r
p
r
o
a
y
u
e
o
r
e
v
e
n
u
e
g
r
o
w
a
n
e
x
p
e
c
e
m
e
s
o
n
e
•
t
p
a
y
m
e
n
s

Agenda

  • •Highlights 2012
  • • Financial performance e 2012
  • • Update on Action Plan 2 2016
  • •Outlook

Adjusted revenue milestonesguidance in Q4 due to shift in

Overview financial guidan nce 2012

i
€
n
m
2
0
1
1		 2
0
1
2		 ∆ G
i
d
a
n
c
e
u
1
)
1
9
O
O
b
b
t
t
c
o
e
r		 G
i
d
a
n
c
e
u
M
M
h
h
a
r
c
R
e
e
n
e
s
v
u		 8
0
1		 8
3
7		 9
%
+		 8
8
9
0
-		 8
8
9
0
-
R
&
D
e
x
p
e
n
s
e
s		 8
4		 8
3		 1
-		 1
0
~		 1
0
~
A
d
j
t
d
t
i
u
s
e
o
p
e
r
a
n
g
2
)
i
n
c
o
m
e		 8
5		 1
4		 6
%
7
-		 f
P
i
b
l
t
r
o
a
e
,
b
b
l
2
0
1
1
t
e
o
u
w		 I
d
m
p
r
o
e
o
e
r
v
v
2
0
1
1
L
i
i
d
i
t
t
d
q
u
y
a
y
e
a
r
e
n		 6
2
4		 6
4
2		 3
%
+		 6
0
>		 6
0
>

Good top-line grow wth but profitability reduced

Key financials FY 2012: Co ondensed profit & loss statement (IFRS)

i
n		 € m
2
0
1
0
A
t
l
c
a
u		 2
0
0
1
1
A
t
l
c
c
a
u		 2
0
1
2
A
t
l
c
a
u		 %
s
v
A
t
l
1
1
c
a
u
R
e
v
e
n
u
e
s		 3
5
5		 8
0
1		 8
3
7		 9
%
+		 A
d
j
d
t
s
e
u
G
i
r
o
s
s
m
a
r
g
n		 4
4
1
%		 4
3
3
%
7		 3
6
%
5		 i
t
o
p
p
e
r
a
n
g
g
R
&
D
e
x
p
e
n
s
e
s
•		 6
1		 8
8
4		 8
3		 1
%
-		 i
f
n
c
o
m
e
o
S
G
&
A
e
p
e
n
s
e
s
x
•		 1
6
0		 1
5
8		 1
6
3		 3
%
+		 €
1
4
m
A
i
i
f
i
i
b
l
t
t
t
t
m
o
r
s
a
o
n
o
n
a
n
g
e
a
s
s
e
s
•		 0
7		 1
1
7		 2
8		 6
3
%
+		 3
0
2
f
E
V
T
t
u
p
r
o
n
I
i
t
m
p
a
r
m
e
n
•		 0
0		 2
2
1		 3
5		 7
0
%
+		 €
6
9
d
d
d
a
e
m
i
2
0
1
1
n
R
l
f
i
i
t
e
e
r
s
a
o
m
p
a
r
m
e
n
v
•		 0
0.		 1
1
5
5
-		 0
0
0
0		 1
1
0
0
0
0
%
%
-
O
h
i
t
t
e
r
o
p
e
r
a
n
g
e
x
p
e
n
s
e
s
•		 0
1
-		 3
3
3		 3
3		 0
%		 f
P
l
l
l
t
l
a
r
a
e
r
e
n
a
o
O
(
)
t
i
i
p
e
r
a
n
g
n
c
o
m
e
e
x
p
e
n
s
e		 1
7
+		 5
2
+		 3
2
-		 %
1
6
1
-		 €
2
3
i
2
0
1
2
m
n
O
i
i
j
d
d
t
t
p
e
r
a
n
g
n
c
o
m
e
a
s
e
u		 1.
7
+		 5
8
+		 1.
4
+		 7
6
%
-		 d
t
t
u
e
o
m
o
v
e
o
N
i
t
e
n
c
o
m
e		 3
0
+		 6
7
+		 2
5
+		 6
3
%
-		 1
)
C
M
E

Good growth, lowe upfronts er margin due to decrease in

Revenues, milestones & gr ross margin

Clear investment fand best-in-class ifocus for first-in-class innovation Xinfrastructures

Overview R&D and CAPEX

in € m

Strong operating c cash flow invested in innovation

Business and cash overvieew

Strong strategic p g gpbalance sheetosition supp y y g orted by very strong

Balance sheet overview

in € m

Q4 op g erating resu contingent consid lt imp yp acted by impairment and erations

Q4 2012 results

in € m

Q
4
2
0
1
1
A
A
l
l
t
t
c
a
u
u		 Q
4
2
0
1
2
A
A
l
l
t
t
c
a
u		 •
R
e
v
e
n
u
e
s		 2
0
4		 2
3
1
G
i
r
o
s
s
m
a
r
g
n		 3
0
0
0
%		 3
3
1
%		 d
l
e
a
R
&
D
e
p
e
n
s
e
s
x
•		 1
7
7		 2
2		 •
S
G
&
A
e
p
e
n
s
e
s
x
•		 4
3
3		 4
0		 V
R
1
A
i
i
t
t
m
o
r
s
a
o
n
•		 0
5
5		 0
8		 •
I
i
t
m
p
a
r
m
e
n
•		 2
1
1		 3
5
O
h
i
t
t
e
r
o
p
e
r
a
n
g
e
x
p
e
n
s
e
s
•		 1
9.
9		 3
3
1
1
O
t
i
l
p
e
r
a
n
g
o
s
s		 4
3
-		 6
1
-
N
l
t
e
o
s
s		 2
5
-		 4
5
-
  • • Higher margin from g g increase in upfronts due to Janssen EVT100 deal
  • • Impairment charge in Q4 mainly due to VR1
  • • Increase in other operating expenses mainly fdue to fair value adjustment on earn out provisions

Agenda

  • •Highlights 2012
  • • Financial performance 2 2012
  • • Update on Action Plan 2016
  • •Outlook

Addressing the R& innovation challen&D p y roductivity and nge with our customers

Evotec's innovation solutions – Action Plan 2016

Broad stand-alonee execution business

Comprehensive drug disco overy platform – "EVO Apps"

Growth driven by outsourcing servic high-q y ualit ces

EVT Execute strategy 2013 3

Expand offering for e xpand customer solutions 1 even more complete

Expand footprint with to our customers 2 h services even closer

Further improve gros 3 profitability through ss margins and lean initiatives

Larg pp e scope pharm with best-in-class maceutical p pi eline partners

EVT Integrate and Innova ate – pre-clinical portfolio

I
d
i
t
i
n
c
a
o
n		 P
t
a
r
n
e
r		 S
t
t
a
s
u		 N
N
t
i
l
t
e
m
e
s
o
n
e
x		 C
i
l
o
m
m
e
r
c
a
s
O
O
l
l
i
i
h
t
n
n
c
c
o
o
o
o
g
g
p
p
a
a
n
n,
o
e
r
s
y
y,		 P
l
l
i
i
i
i
l
l
r
e-
c
c
n
n
c
c
a
a		 P
P
l
l
i
i
i
i
l
l
d
d
i
i
d
d
t
t
r
e-
c
c
n
n
c
c
a
a
c
c
a
a
n
n
a
a
e
e
s
s,
C
C
l
i
i
l
P
h
I
t
t
n
c
a
a
s
e
s
a
r		 f
f
R
h
d
d
i
i
i
l
t
t
e
s
e
a
r
c
n
n
n
n
g
g
m
e
s
o
n
e
p
a
m
e
n
s
u
u
y
,
d
l
i
t
a
n
r
o
y
a
e
s
E
d
i
i
t
n
o
m
e
r
o
s
s		 P
l
i
i
l
r
e-
c
n
c
a		 V
V
l
i
d
d
t
t
t
a
a
e
a
r
g
e
s
P
P
l
i
i
l
d
i
d
t
r
e-
c
n
c
a
c
a
n
a
e
s		 U
f
€
1
2
l
l
t
t
t
t
p
r
o
n
m
o
a
a
e
p
o
;
v
u
u
€
8
0
l
i
5
t
m
r
o
a
e
s
;
y
U
d
i
l
d
n
s
c
o
s
e		 P
l
i
i
l
r
e-
c
n
c
a		 P
P
h
I
I
l
i
t
a
s
e
c
o
m
p
e
o
n,
)
1
l
i
i
l
P
h
I
c
c
n
c
a
a
s
e		 f
f
U
h
d
i
t
t,
p
r
o
n
p
a
m
e
n
r
e
s
e
a
r
c
n
n
g
y
u
,
i
l
d
l
i
t
t
t
m
e
s
o
n
e
p
a
y
m
e
n
s
a
n
r
o
y
a
e
s
V
i
a
r
o
s
u		 P
l
i
i
l
r
e-
c
n
c
a		 P
P
l
i
i
l
d
i
d
t
r
e-
c
n
c
a
c
a
n
a
e
s		 f
R
h
d
i
i
l
t
t
e
s
e
a
r
c
n
n
g
m
e
s
o
n
e
p
a
m
e
n
s
u
y
,
d
l
i
t
a
n
r
o
y
a
e
s
T
2
D
i
b
t
p
e
a
e
e
s
y
S
I
l
i
i
i
t
n
s
u
n
e
n
s
z
e
r		 R
h
e
s
e
a
r
c		 P
P
l
i
i
l
d
i
d
t
r
e-
c
n
c
a
c
a
n
a
e		 U
€
2
3
i
l
i
i
f
i
t
7
t
t
p
o
m
m
e
s
o
n
e
s,
s
g
n
c
a
n
l
i
t
r
o
a
e
s
y
T
1
d
2
D
i
b
t
p
e
a
n
a
e
e
s
y		 R
h
e
s
e
a
r
c		 C
C
l
i
i
l
d
i
d
t
n
c
a
c
a
n
a
e		 U
€
2
4
i
l
i
i
f
i
t
5
t
t
p
o
m
m
e
s
o
n
e
s,
s
g
n
c
a
n
l
i
t
r
o
a
e
s
y
C
B
t
e
a
u
r
e
T
1
d
2
D
i
b
t
p
e
a
n
a
e
e
s
y		 R
h
e
s
e
a
r
c		 P
P
l
i
i
l
d
i
d
t
r
e-
c
n
c
a
c
a
n
a
e		 \$
U
f
8
h
t
t
t
p
r
o
n
m
r
e
s
e
a
r
c
p
a
m
e
n
p
o
;
y
;
u
\$
3
0
0
i
l
d
t
t
m
m
e
s
o
n
e
s
p
e
r
p
r
o
c
u
;
i
i
f
i
l
i
t
t
s
g
n
c
a
n
r
o
a
e
s
y

Building an even s of partnerships strong p erortfolio

EVT Integrate strategy 20 13

Further expansion of strategic multi-target 1 f portfolio with new new t alliances

Increase amount of min ongoing alliances 2 milestone achievements

Expand customer rea 3 customer biotech and mid-size ach to even more ed Pharma customers

Significant pipelin e events upcoming

EVT Innovate – clinical deevelopment assets

I
d
i
t
i
n
c
a
o
n		 P
t
a
r
n
e
r		 S
t
t
a
u
s		 N
N
t
i
l
t
e
x
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
1
)
D
i
b
t
a
e
e
s		 d
2
P
h
I
I
I
n
a
s
e
i
l
d
t
t
r
e
c
r
u
m
e
n
c
o
s
e		 F
F
i
l
P
h
I
I
I
d
t
n
a
a
s
e
a
a		 U
€
4
0
i
i
l
l
l
i
t
t
t
t
p
o
m
m
m
e
e
s
s
o
o
n
n
e
e
s
s,
r
o
a
e
s
y
;
i
l
k
€
0
0
t
t
t
5
p
o
e
n
a
m
a
r
e
a
p
p
r
o
m
x.
A
l
h
i
's
z
e
m
e
r
)
2
d
i
s
e
a
s
e		 P
h
I
I
t
t
a
s
e
s
a
r		 C
C
l
i
f
P
h
I
I
/
t
o
m
p
e
o
n
o
a
s
e
P
P
h
I
I
I
t
t
a
s
e
s
a
r		 \$
U
i
l
l
i
8
2
0
t
t
t
p
o
m
m
e
s
o
n
e
s,
r
o
y
a
e
s
;
\$
i
l
k
b
3
3-
5
t
t
t
p
o
e
n
a
m
a
r
e
n
T
i
t
t-
t
t
r
e
a
m
e
n
r
e
s
s
a
n
)
3
d
i
e
p
r
e
s
s
o
n		 P
h
I
I
t
t
a
s
e
s
a
r		 C
C
f
f
i
i
t
o
n
r
m
a
o
n
o
p
r
e
l
i
i
l
d
/
P
h
I
I
t
c
c
n
c
a
s
u
y
a
s
e
t
t
s
s
a
r		 \$
U
1
6
0
i
l
l
i
t
t
t
p
o
m
m
e
s
o
n
e
s,
r
o
y
a
e
s
;
\$
i
l
k
b
2
t
t
t
p
o
e
n
a
m
a
r
e
n
)
4
f
I
l
i
t
n
a
m
m
a
o
n		 /
P
h
I
I
I
a
s
e		 P
P
h
I
I
t
t
a
s
e
s
a
r		 U
€
6
0
i
l
l
i
t
t
t
p
o
m
m
e
s
o
n
e
s,
r
o
y
a
e
s
)
5
I
i
n
s
o
m
n
a		 P
h
I
I
a
s
e		 P
P
h
I
I
b
t
t
a
s
e
s
a
r		 M
i
l
l
i
t
t
e
s
o
n
e
s,
r
o
y
a
e
s
A
l
d
i
b
i
t
c
r
o
m
e
g
a
y,
a
e
c
i
h
h
t
t
t
r
e
n
o
p
p
a
y,
y,
o
e
r
s		 P
h
I
a
s
e		 P
P
i
t
a
r
n
e
r
n
g		 f
A
d
i
l
i
t
v
s
o
r
y
e
e
s,
r
o
y
a
e
s
V
i
a
r
o
s
u		 e
g		 P
l
i
i
l
r
e-
c
n
c
a		 P
P
h
I
t
t
a
s
e
s
a
r		 M
i
l
l
i
t
t
e
s
o
n
e
s,
r
o
a
e
s
y

Overview pipeline highligh hts

Harvard & Yale as partners for Cure X strategy

Cure Xoverview

C
B
t
e
a
u
r
e		 S
d
l
l
b
i
i
h
H
d
U
i
i
i
M
h
2
0
1
1
t
t
t
t
t
a
r
e
c
o
a
o
r
a
o
n
a
r
a
r
n
e
r
s
n
a
r
c
w
v
v
y
•
C
P
d
B
i
h
J
J
i
J
l
2
0
1
2
t
t
t
a
r
n
e
r
e
u
r
e
e
a
w
a
n
s
s
e
n
n
u
y
•
S
f
i
i
i
h
i
l
l
i
t
t
t
t
g
n
c
a
n
r
e
s
e
a
r
c
p
a
y
m
m
e
n
s
m
e
s
o
n
e
s
r
o
y
a
e
s
•
,
,
C
N
h
e
p
r
o
n
u
r
e		 S
d
l
l
b
i
i
h
H
d
U
i
i
i
J
2
0
1
2
t
t
t
t
t
a
r
e
c
o
a
o
r
a
o
n
w
a
r
v
a
r
n
v
e
r
s
y
n
a
n
u
a
r
y
•
P
f
l
i
f
h
i
d
i
f
d
i
d
i
f
i
h
i
t
t
t
o
r
o
o
o
a
p
p
r
o
a
c
e
s
o
e
n
s
e
a
s
e
-m
o
n
g
m
e
c
a
n
s
m
s
y
y
•
H
i
h
l
d
i
i
i
d
i
d
t
t
t
t
t
g
y
p
r
o
u
c
v
e
n
g
e
n
e
r
r
a
n
g
c
a
n
a
e
a
r
g
e
s
•
C
X
u
r
e		 C
h
f
l
i
l
d
l
j
t
t
t
t
o
n
c
e
p
p
a
s
e
o
r
s
e
e
r
a
n
e
r
n
a
a
n
e
e
r
n
a
p
r
o
e
c
s
v
x
•
E
l
i
i
l
i
d
l
l
b
i
i
i
t
t
t
t
t
t
t
p
o
r
n
g
p
o
e
n
a
n
e
s
m
m
e
n
s
a
n
c
o
a
o
r
a
o
n
o
p
p
o
r
n
e
s
x
v
u
•

First-in-class prod ducts candidates

EVT Innovate strategy 201 13

2

3

St t f l li i 1 Start of several clinic alliancescalti l r as withi i ti ithin existing

Commercialise one C Cure Xinitiative

I iti ti f 1 Initiation of 1-2 more e Cure Xi iti ti initiatives

Agenda

  • •Operational Highlights
  • •Financial performance
  • • Update on Action Plan 2 2016
  • •Outlook

Good revenue gro performance in 20 owth and improved financial 013

Guidance 2013: Organic g rowth, higher profitability, more innovation

Accelerated innovvation strategy

Key metrics for 2013

in € m

Strong news flow to come with Action Plan 2016

Outlook and next steps for r 2013 ff

Key milestones for 2013

1
  • • Revenue growth and inc creased gross margin
  • EVT Execute Expansion success of ex xisting alliances
  • • Significant long-term dea als with big and mid-sized Pharma and biotech

• At least 1 significant new • Accelerated pre-clinical/ 2 EVT Integrate w integrated technology/disease alliance /clinical milestones

3EVT Innovate

  • • Strong progress in produ uct development partnerships
  • • Expansion of network of academic alliances
  • • Partnering of one pre-clin nical asset/development programme

Reporting dates 2013:

  • •3M/Q1 i t i t interim report 14 M ay
  • •AGM in Hamburg 12 June
  • •6M/Q2 interim report 08 August
  • •Capital Market/R&D Day September/October
  • •9M/Q3 interim report 12 November

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax [email protected]

More from Evotec SE

Director's Dealing 2026
May 22
Major Shareholding Notification 2026
May 21
Major Shareholding Notification 2026
May 19
Major Shareholding Notification 2026
May 18
Capital/Financing Update 2026
May 12
Regulatory Filings 2026
May 7
Interim / Quarterly Report 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Major Shareholding Notification 2026
May 5
View all filings →